Ondansetron

Ondansetron is an antiemetic, a drug that prevents nausea and vomiting, and it belongs to the class of selective serotonin 5-HT3 receptor antagonists, sometimes called setrons ^[1]. It was among the first agents developed to block this specific serotonin receptor for controlling vomiting, and its arrival marked a substantial advance in managing chemotherapy-induced sickness ^[2]. The drug is well absorbed when taken by mouth, is broken down in the liver, and has a duration of action that allows dosing a few times a day ^[1].

Ondansetron was developed by researchers at Glaxo, later GlaxoSmithKline, during the 1980s and received United States approval in 1991, marketed as Zofran ^[2]. For years it was a leading branded medicine, and after its patents expired it became broadly available as an inexpensive generic. Related 5-HT3 antagonists, such as granisetron and palonosetron, were introduced later and share the same basic mechanism.

The drug is used to prevent and treat nausea and vomiting from several causes. Its best-established roles are in sickness caused by cancer chemotherapy and radiation therapy and in postoperative nausea and vomiting after anesthesia ^[3][4]. Network meta-analyses comparing antiemetics place 5-HT3 antagonists among the effective options in both the surgical and chemotherapy settings, often used together with other classes of drug for stronger protection ^[3][4]. It is also given off-label for nausea from other causes, such as gastroenteritis, and a clearer understanding of the nausea and vomiting pathways has helped explain where these drugs act ^[2].

Ondansetron is a prescription medicine available as ordinary tablets, orally dissolving tablets, oral liquid, and solutions for injection into a muscle or vein ^[1]. It is generally well tolerated, with headache, constipation, and fatigue among the more common effects ^[1]. A notable safety consideration is that it can prolong the heart's QT interval, an effect on cardiac electrical timing that in rare cases can lead to dangerous rhythms; because of this, a very high single intravenous dose was withdrawn from use, and the drug is given with care to people with certain heart conditions or electrolyte disturbances ^[1].

Ondansetron is generally very well tolerated and, unlike older anti-sickness drugs, is largely non-sedating. Common effects are headache, constipation, fatigue and dizziness. Its main safety issue is a dose-related prolongation of the QT interval, so single intravenous doses above 16 mg are avoided and care is needed in people with congenital long QT, low potassium or magnesium, or other QT-prolonging drugs. It should not be combined with apomorphine, which can cause severe low blood pressure, and there is a small serotonin syndrome risk when it is added to other serotonergic medicines. On that serotonin syndrome point: a clinical commentary argues the WHO, FDA and Health Canada warnings about 5-HT3 antagonists plus serotonergic drugs rest on an implausible mechanism, and that 5-HT3 antagonists like ondansetron are actually unlikely to cause serotonin toxicity.

Ondansetron prolongs the QT interval, and the FAERS database identified ondansetron among the nine most frequently implicated drugs in fatal torsades de pointes cases ^[17]. High-risk combinations involving other QT-prolonging drugs include citalopram and escitalopram (both SSRI antidepressants that prolong QT), amiodarone (an antiarrhythmic), and ciprofloxacin (a fluoroquinolone antibiotic). The interaction is pharmacodynamic; both drugs independently prolong cardiac repolarization, and concurrent use compounds this effect. What is not well-studied: ondansetron with tricyclic antidepressants, first-generation antihistamines, or antipsychotics at typical doses in patients without underlying QT prolongation risk factors.

Checking a whole stack? Run it through interactions + stacks.

Ondansetron emerged from research at the British pharmaceutical company Glaxo during the 1980s, part of a deliberate effort to understand the newly appreciated role of serotonin 5-HT3 receptors in the vomiting reflex. Scientists recognized that cytotoxic chemotherapy triggered nausea partly by causing serotonin release in the gut, and that selectively blocking 5-HT3 receptors might interrupt that signal without the sedation and movement disorders of older antiemetics.

The resulting compound was approved in 1991 and marketed as Zofran, and it revolutionized supportive cancer care by making highly emetogenic chemotherapy far more tolerable, later extending to radiation-induced and postoperative nausea. An orally dissolving formulation and the film product Zuplenz broadened its convenience for patients unable to swallow tablets. In the decades since, its clean receptor selectivity has invited extensive repurposing research, and it remains a first-choice antiemetic on the World Health Organization Model List of Essential Medicines.

Ondansetron is widely regarded as a breakthrough that changed the experience of cancer treatment, taming the debilitating nausea and vomiting of chemotherapy and doing so with far less sedation than the antiemetics that preceded it. Its selective action on 5-HT3 receptors gives it a clean, predictable profile that made it a mainstay in oncology, surgery, and emergency care, and its availability as a mouth-dissolving tablet is a genuine practical advantage for patients who cannot keep anything down.

The same specificity has fueled intriguing repurposing work: controlled trials found it reduced drinking in early-onset alcohol use disorder, with response predicted by serotonin transporter and 5-HT3 receptor genotypes, an early example of pharmacogenetically guided addiction treatment, and it has shown promise in diarrhea-predominant irritable bowel syndrome. In the interest of balance, its main safety consideration is a dose-dependent prolongation of the heart's QT interval, so single high intravenous doses are avoided and caution applies in patients with cardiac risk factors; constipation and headache are the common everyday effects.